GLSI · Greenwich LifeSciences, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The Company has prepared its financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.”View the 10-Q filed Aug 11, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GLSI
this stock
Greenwich LifeSciences, Inc.
|
$269.93M | -9.6% | — | — | 11.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.06B | +12.1% | +46.2% | 29.9 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.80B | +1.7% | +20.8% | 19.4 | 2.5% |
|
MRNA
Moderna, Inc.
|
$61.50B | +422.3% | +4.3% | — | 9.8% |
|
ARGX
Argenx SE
|
$60.93B | +17.8% | — | — | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GLSI | +22.9% | +24.0% | -15.0% | +27.0% | -9.6% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | +23.3% | +24.2% | -35.1% | +27.7% | -21.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.